Top

BMC Cancer

Published in:

01-12-2021 | Cervical Cancer | Research

Bioinformatics analysis of differentially expressed genes and pathways in the development of cervical cancer

Authors: Baojie Wu, Shuyi Xi

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

This study aimed to explore and identify key genes and signaling pathways that contribute to the progression of cervical cancer to improve prognosis.

Methods

Three gene expression profiles (GSE63514, GSE64217 and GSE138080) were screened and downloaded from the Gene Expression Omnibus database (GEO). Differentially expressed genes (DEGs) were screened using the GEO2R and Venn diagram tools. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Gene set enrichment analysis (GSEA) was performed to analyze the three gene expression profiles. Moreover, a protein–protein interaction (PPI) network of the DEGs was constructed, and functional enrichment analysis was performed. On this basis, hub genes from critical PPI subnetworks were explored with Cytoscape software. The expression of these genes in tumors was verified, and survival analysis of potential prognostic genes from critical subnetworks was conducted. Functional annotation, multiple gene comparison and dimensionality reduction in candidate genes indicated the clinical significance of potential targets.

Results

A total of 476 DEGs were screened: 253 upregulated genes and 223 downregulated genes. DEGs were enriched in 22 biological processes, 16 cellular components and 9 molecular functions in precancerous lesions and cervical cancer. DEGs were mainly enriched in 10 KEGG pathways. Through intersection analysis and data mining, 3 key KEGG pathways and related core genes were revealed by GSEA. Moreover, a PPI network of 476 DEGs was constructed, hub genes from 12 critical subnetworks were explored, and a total of 14 potential molecular targets were obtained.

Conclusions

These findings promote the understanding of the molecular mechanism of and clinically related molecular targets for cervical cancer.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88–102. https://doi.org/10.1016/j.canlet.2019.11.039.CrossRefPubMed

Pinto AP, Crum CP. Natural history of cervical neoplasia: defining progression and its consequence. Clin Obstet Gynecol. 2000;43(2):352–62. https://doi.org/10.1097/00003081-200006000-00015.CrossRefPubMed

den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112(25):E3255–64. https://doi.org/10.1073/pnas.1509322112.CrossRef

Babion I, Miok V, Jaspers A, Huseinovic A, Steenbergen RDM, van Wieringen WN, et al. Identification of deregulated pathways, key regulators, and novel miRNA-mRNA interactions in HPV-mediated transformation. Cancers (Basel). 2020;12(3):700.

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–5. https://doi.org/10.1093/nar/gks1193.CrossRefPubMed

Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10. https://doi.org/10.1093/nar/30.1.207.CrossRefPubMedPubMedCentral

Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35(Web Server issue):W169–75.CrossRefPubMedPubMedCentral

Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

10.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

11.

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73. https://doi.org/10.1038/ng1180.CrossRefPubMed

12.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d613. https://doi.org/10.1093/nar/gky1131.CrossRefPubMed

13.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504. https://doi.org/10.1101/gr.1239303.CrossRefPubMedPubMedCentral

14.

Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4(1):2. https://doi.org/10.1186/1471-2105-4-2.CrossRefPubMedPubMedCentral

15.

Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8 Suppl 4(Suppl 4):S11.CrossRefPubMed

16.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102. https://doi.org/10.1093/nar/gkx247.CrossRefPubMedPubMedCentral

17.

Dasgupta S, Ewing-Graham PC, Swagemakers SMA, van der Spek PJ, van Doorn HC, Noordhoek Hegt V, et al. Precursor lesions of vulvar squamous cell carcinoma - histology and biomarkers: a systematic review. Crit Rev Oncol Hematol. 2020;147:102866. https://doi.org/10.1016/j.critrevonc.2020.102866.CrossRefPubMed

18.

Leal SM Jr, Gulley ML. Current and emerging molecular tests for human papillomavirus-related neoplasia in the genomic era. J Mol Diagn. 2017;19(3):366–77. https://doi.org/10.1016/j.jmoldx.2017.01.006.CrossRefPubMedPubMedCentral

19.

Zhao Q, Li H, Zhu L, Hu S, Xi X, Liu Y, et al. Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer. Biomed Rep. 2020;13(4):21. https://doi.org/10.3892/br.2020.1328.CrossRefPubMedPubMedCentral

20.

Mathevet P, Frappart L, Hittelman W. Cervix dysplasias: study of Rb and p53 gene expression and correlation with mitotic activity. Gynecol Obstet Fertil. 2000;28(1):44–50.PubMed

21.

Wen X, Liu S, Cui M. Effect of BRCA1 on the concurrent Chemoradiotherapy resistance of cervical squamous cell carcinoma based on transcriptome sequencing analysis. Biomed Res Int. 2020;2020:3598417.PubMedPubMedCentral

22.

Zhou YH, Fan WF, Deng J, Xi HL. Establishment and analysis of the prediction model for cervical squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2017;21(22):5042–8. https://doi.org/10.26355/eurrev_201711_13816.CrossRefPubMed

23.

Suman S, Mishra A. An interaction network driven approach for identifying biomarkers for progressing cervical intraepithelial neoplasia. Sci Rep. 2018;8(1):12927. https://doi.org/10.1038/s41598-018-31187-x.CrossRefPubMedPubMedCentral

24.

Guo W, Yu H, Zhang L, Chen X, Liu Y, Wang Y, et al. Effect of hyperoside on cervical cancer cells and transcriptome analysis of differentially expressed genes. Cancer Cell Int. 2019;19(1):235. https://doi.org/10.1186/s12935-019-0953-4.CrossRefPubMedPubMedCentral

25.

Manavi M, Hudelist G, Fink-Retter A, Gschwandtler-Kaulich D, Pischinger K, Czerwenka K. Gene profiling in pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol. 2007;105(2):418–26. https://doi.org/10.1016/j.ygyno.2006.12.032.CrossRefPubMed

26.

Yang C, Xu X, Jin H. Identification of potential miRNAs and candidate genes of cervical intraepithelial neoplasia by bioinformatic analysis. Eur J Gynaecol Oncol. 2016;37(4):469–73.PubMed

27.

Iancu IV, Botezatu A, Goia-Ruşanu CD, Stănescu A, Huică I, Nistor E, et al. TGF-beta signalling pathway factors in HPV-induced cervical lesions. Roum Arch Microbiol Immunol. 2010;69(3):113–8.PubMed

28.

Zong S, Liu X, Zhou N, Yue Y. E2F7, EREG, miR-451a and miR-106b-5p are associated with the cervical cancer development. Arch Gynecol Obstet. 2019;299(4):1089–98. https://doi.org/10.1007/s00404-018-5007-y.CrossRefPubMed

29.

Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011;11(1):80. https://doi.org/10.1186/1471-2407-11-80.CrossRefPubMedPubMedCentral

30.

Li S, Liu N, Piao J, Meng F, Li Y. CCNB1 expedites the progression of cervical squamous cell carcinoma via the regulation by FOXM1. Onco Targets Ther. 2020;13:12383–95. https://doi.org/10.2147/OTT.S279951.CrossRefPubMedPubMedCentral

31.

Wu K, Yi Y, Liu F, Wu W, Chen Y, Zhang W. Identification of key pathways and genes in the progression of cervical cancer using bioinformatics analysis. Oncol Lett. 2018;16(1):1003–9. https://doi.org/10.3892/ol.2018.8768.CrossRefPubMedPubMedCentral

32.

Klymenko T, Gu Q, Herbert I, Stevenson A, Iliev V, Watkins G, et al. RNA-Seq Analysis of differentiated keratinocytes reveals a massive response to late events during human papillomavirus 16 infection, including loss of epithelial barrier function. J Virol. 2017;91(24):e01001–17.

33.

Liu J, Nie S, Gao M, Jiang Y, Wan Y, Ma X, et al. Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis. J Cell Physiol. 2019;234(11):21260–73. https://doi.org/10.1002/jcp.28731.CrossRefPubMed

34.

Qiu HZ, Huang J, Xiang CC, Li R, Zuo ED, Zhang Y, et al. Screening and discovery of new potential biomarkers and small molecule drugs for cervical Cancer: a bioinformatics analysis. Technol Cancer Res Treat. 2020;19:1533033820980112.PubMedPubMedCentral

35.

Yang HJ, Xue JM, Li J, Wan LH, Zhu YX. Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis. Mol Genet Genomic Med. 2020;8(6):e1200. https://doi.org/10.1002/mgg3.1200.CrossRefPubMedPubMedCentral

36.

Xie Q, Ou-Yang W, Zhang M, Wang H, Yue Q. Decreased expression of NUSAP1 predicts poor overall survival in cervical Cancer. J Cancer. 2020;11(10):2852–63. https://doi.org/10.7150/jca.34640.CrossRefPubMedPubMedCentral

37.

van Dam PA, Rolfo C, Ruiz R, Pauwels P, Van Berckelaer C, Trinh XB, et al. Potential new biomarkers for squamous carcinoma of the uterine cervix. ESMO Open. 2018;3(4):e000352. https://doi.org/10.1136/esmoopen-2018-000352.CrossRefPubMedPubMedCentral

38.

Xue JM, Liu Y, Wan LH, Zhu YX. Comprehensive analysis of differential gene expression to identify common gene signatures in multiple cancers. Med Sci Monit. 2020;26:e919953.PubMedPubMedCentral

39.

Wu DM, Shi J, Liu T, Deng SH, Han R, Xu Y. Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression. Cancer Biomark. 2018;21(2):355–65. https://doi.org/10.3233/CBM-170501.CrossRefPubMed

40.

Yuan Y, Shi X, Li B, Peng M, Zhu T, Lv G, et al. Integrated analysis of key microRNAs /TFs /mRNAs/ in HPV-positive cervical cancer based on microRNA sequencing and bioinformatics analysis. Pathol Res Pract. 2020;216(6):152952. https://doi.org/10.1016/j.prp.2020.152952.CrossRefPubMed

41.

Yi Y, Liu Y, Wu W, Wu K, Zhang W. Reconstruction and analysis of circRNA-miRNA-mRNA network in the pathology of cervical cancer. Oncol Rep. 2019;41(4):2209–25. https://doi.org/10.3892/or.2019.7028.CrossRefPubMedPubMedCentral

42.

Bourmenskaya O, Shubina E, Trofimov D, Rebrikov D, Sabdulaeva E, Nepsha O, et al. Host gene expression profiling of cervical smear is eligible for cancer risk evaluation. J Clin Pathol. 2013;66(4):282–5. https://doi.org/10.1136/jclinpath-2012-201313.CrossRefPubMed

43.

Zhao L, Zhang Z, Lou H, Liang J, Yan X, Li W, et al. Exploration of the molecular mechanisms of cervical cancer based on mRNA expression profiles and predicted microRNA interactions. Oncol Lett. 2018;15(6):8965–72. https://doi.org/10.3892/ol.2018.8494.CrossRefPubMedPubMedCentral

44.

Papasavvas E, Kossenkov AV, Azzoni L, Zetola NM, Mackiewicz A, Ross BN, et al. Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women. Carcinogenesis. 2019;40(2):225–33. https://doi.org/10.1093/carcin/bgy149.CrossRefPubMed

45.

Kaur G, Balasubramaniam SD, Lee YJ, Balakrishnan V, Oon CE. Minichromosome maintenance complex (MCM) genes profiling and MCM2 protein expression in cervical Cancer development. Asian Pac J Cancer Prev. 2019;20(10):3043–9. https://doi.org/10.31557/APJCP.2019.20.10.3043.CrossRefPubMedPubMedCentral

46.

Xu Z, Zhou Y, Shi F, Cao Y, Dinh TLA, Wan J, et al. Investigation of differentially-expressed microRNAs and genes in cervical cancer using an integrated bioinformatics analysis. Oncol Lett. 2017;13(4):2784–90. https://doi.org/10.3892/ol.2017.5766.CrossRefPubMedPubMedCentral

47.

Mine KL, Shulzhenko N, Yambartsev A, Rochman M, Sanson GF, Lando M, et al. Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer. Nat Commun. 2013;4(1):1806. https://doi.org/10.1038/ncomms2693.CrossRefPubMed

48.

van Dam PA, van Dam PJ, Rolfo C, Giallombardo M, van Berckelaer C, Trinh XB, et al. In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment. Oncotarget. 2016;7(3):2780–95. https://doi.org/10.18632/oncotarget.6667.CrossRefPubMed

49.

Luo Y, Wu Y, Peng Y, Liu X, Bie J, Li S. Systematic analysis to identify a key role of CDK1 in mediating gene interaction networks in cervical cancer development. Ir J Med Sci. 2016;185(1):231–9. https://doi.org/10.1007/s11845-015-1283-8.CrossRefPubMed

50.

Jiang L, Zeng X, Wang Z, Ji N, Zhou Y, Liu X, et al. Oral cancer overexpressed 1 (ORAOV1) regulates cell cycle and apoptosis in cervical cancer HeLa cells. Mol Cancer. 2010;9(1):20. https://doi.org/10.1186/1476-4598-9-20.CrossRefPubMedPubMedCentral

51.

Mou Z, Xu X, Dong M, Xu J. MicroRNA-148b acts as a tumor suppressor in cervical Cancer by inducing G1/S-phase cell cycle arrest and apoptosis in a Caspase-3-dependent manner. Med Sci Monit. 2016;22:2809–15. https://doi.org/10.12659/MSM.896862.CrossRefPubMedPubMedCentral

52.

Xie Y, Shen YT, Kapoor A, Ojo D, Wei F, De Melo J, et al. Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle. Data Brief. 2016;6:811–6. https://doi.org/10.1016/j.dib.2016.01.036.CrossRefPubMedPubMedCentral

53.

Zhao JL, Zhang L, Guo X, Wang JH, Zhou W, Liu M, et al. miR-212/132 downregulates SMAD2 expression to suppress the G1/S phase transition of the cell cycle and the epithelial to mesenchymal transition in cervical cancer cells. IUBMB Life. 2015;67(5):380–94. https://doi.org/10.1002/iub.1381.CrossRefPubMed

54.

Das M, Prasad SB, Yadav SS, Modi A, Singh S, Pradhan S, et al. HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4. Tumour Biol. 2015;36(12):9987–94. https://doi.org/10.1007/s13277-015-3782-7.CrossRefPubMed

55.

Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, et al. mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev. 2009;18(1):40–5. https://doi.org/10.1097/CEJ.0b013e32830c8d5a.CrossRefPubMed

56.

Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, et al. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer. 2007;97(8):1124–34. https://doi.org/10.1038/sj.bjc.6603992.CrossRefPubMedPubMedCentral

57.

Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007;96(11):1711–5. https://doi.org/10.1038/sj.bjc.6603784.CrossRefPubMedPubMedCentral

58.

Zhang X, Teng Y, Yang F, Wang M, Hong X, Ye LG, et al. MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas. Oncol Rep. 2015;33(5):2599–605. https://doi.org/10.3892/or.2015.3822.CrossRefPubMed

59.

Zheng J. Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection. Int J Clin Exp Pathol. 2015;8(1):875–80.PubMedPubMedCentral

60.

Liu D, Zhang XX, Xi BX, Wan DY, Li L, Zhou J, et al. Sine oculis homeobox homolog 1 promotes DNA replication and cell proliferation in cervical cancer. Int J Oncol. 2014;45(3):1232–40. https://doi.org/10.3892/ijo.2014.2510.CrossRefPubMed

61.

Niu G, Wang D, Pei Y, Sun L. Systematic identification of key genes and pathways in the development of invasive cervical cancer. Gene. 2017;618:28–41. https://doi.org/10.1016/j.gene.2017.03.018.CrossRefPubMed

62.

Yan R, Shuai H, Luo X, Wang X, Guan B. The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis. Biosci Rep. 2017;37(5):BSR20171021.

63.

Bai L, Yao N, Qiao G, Wu L, Ma X. CXCL5 contributes to the tumorigenicity of cervical cancer and is post-transcriptionally regulated by miR-577. Int J Clin Exp Pathol. 2020;13(12):2984–93.PubMedPubMedCentral

64.

Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao Y, et al. TOP2A and CENPF are synergistic master regulators activated in cervical cancer. BMC Med Genet. 2020;13(1):145. https://doi.org/10.1186/s12920-020-00800-2.CrossRef

65.

Chen H, Wang X, Jia H, Tao Y, Zhou H, Wang M, et al. Bioinformatics analysis of key genes and pathways of cervical Cancer. Onco Targets Ther. 2020;13:13275–83. https://doi.org/10.2147/OTT.S281533.CrossRefPubMedPubMedCentral

66.

Ouyang F, Liu J, Xia M, Lin C, Wu X, Ye L, et al. GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer. Oncol Rep. 2017;37(5):2652–62. https://doi.org/10.3892/or.2017.5573.CrossRefPubMedPubMedCentral

67.

Zhang W, He W, Shi Y, Gu H, Li M, Liu Z, et al. High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma. PLoS One. 2016;11(12):e0167449. https://doi.org/10.1371/journal.pone.0167449.CrossRefPubMedPubMedCentral

Title: Bioinformatics analysis of differentially expressed genes and pathways in the development of cervical cancer
Authors: Baojie Wu
Shuyi Xi
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Cervical Cancer
Cervical Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08412-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy

The neuropeptide calcitonin gene-related peptide links perineural invasion with lymph node metastasis in oral squamous cell carcinoma

TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma

Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer